8-K filing — VOLITIONRX LTD (VNRX)
Filed: 2026-09-02 AccNo: 0001477932-26-005359 Size: 172 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
VolitionRx Announces Publication Of Peer-Reviewed Paper And Editorial Indicating That Its Nu.Q NETs H3.1 Biomarker Is An Independent Predictor Of 28-Day Mortality And Need For Renal Replacement Therapy In Sepsis And Septic Shock Patients
Entitled "H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial1" and published in Critical Care Medicine, the findings
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
VolitionRX shares are trading lower after the company filed a prospectus for an offering of 10 million shares.
Volitionrx Files Prospectus For Offering 10M Common Shares On Behalf Of Selling Shareholders
SEC.
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results
US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings. Propanc Biopharma up 211%, VolitionRX up 86%, Mint Incorporation up 74%, Alpha Modus down 25%, Change Agents down 29%, and Xiao-I down 21%.